Teva Submits NDA for Once-Monthly Olanzapine Injection for Schizophrenia
Teva Pharmaceuticals Files New Drug Application with FDA for Once-Monthly Olanzapine Extended-Release Injectable Suspension (TEV-‘749) to Treat Schizophrenia in Adults Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.,…
ICON 2025 Survey Shows China Leading Biotech, Highlights Opportunities for Western Firms
ICON plc, a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023…
AskBio’s AB-1005 and AB-1002 Granted Japan’s Pioneering Regenerative Medicine Product Designation
AskBio’s AB-1005 and AB-1002 Granted Pioneering Regenerative Medicine Product Designation in Japan AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today…
CVS Health Revises Guidance, Showcases Business Strength, and Unveils Healthcare Reimagining Strategy at Investor Day
CVS Health Revises Financial Outlook, Showcases Business Strength, and Unveils Bold Strategy to Redefine Health Care at Investor Day CVS Health® will launch its strategy to deliver best-in-class execution, transform…
BioNTech & BMS Report Promising Phase 2 Results for Pumitamig in Advanced Triple-Negative Breast Cancer
BioNTech and Bristol Myers Squibb Unveil Promising Phase 2 Global Data for Pumitamig—First PD-L1xVEGF-A Bispecific Antibody—Demonstrating Encouraging Efficacy in Advanced Triple-Negative Breast Cancer BioNTech SE and Bristol Myers Squibb Company today announced the…
Novartis’ Ianalumab Extends Disease Control in Immune Thrombocytopenia with Just Four Monthly Doses
Novartis’ Ianalumab Provides Sustained Disease Control in Immune Thrombocytopenia Patients with Just Four Monthly Doses Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in…
Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Vaginitis in Women
Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Women with Vaginitis Roche announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately…
MajesTEC-3: TECVAYLI + DARZALEX FASPRO Shows Potential as New Second-Line Standard in RR Multiple Myeloma
Phase 3 MajesTEC-3 Study Delivers Unprecedented Results, Positioning TECVAYLI® Plus DARZALEX FASPRO® as a Potential New Standard of Care as Early as Second-Line Treatment for Relapsed/Refractory Multiple Myeloma Johnson &…
Lilly to Invest $6B in New Alabama API Manufacturing Facility
Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama.…
Jim Lang Joins Halozyme’s Board, Bringing 30+ Years of Leadership Experience
Jim Lang Elected to Halozyme’s Board of Directors Halozyme Therapeutics, Inc. today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of…
Global experts convene in Vienna to discuss radiation protection in medicine
Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by…
Genmab Reports Promising Epcoritamab Data in Richter Transformation from EPCORE® CLL-1 Trial
Genmab Unveils New Phase 1b/2 EPCORE® CLL-1 Data Showcasing Epcoritamab’s Promise as Monotherapy and in Combination for Richter Transformation Patients Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial evaluating the efficacy and…